CA-GLOBALITY
29.7.2021 14:02:13 CEST | Business Wire | Press release
Globality , the leading AI-powered digital solution for sourcing services, and Allegis Global Solutions (AGS), the leading provider of global workforce solutions, today announced a partnership that transforms services procurement management so organizations can realize the maximum value from their services spend.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005144/en/
By closing the loop between sourcing and spend management, the partnership will deliver increased value through the end-to-end procurement process, incorporating AI-powered insights every step of the way. As a result, AGS customers will benefit from real-time data and intelligence on supplier performance in Globality’s self-serve Platform, leading to better buying decisions.
“Today’s workforce is dramatically different than it was a year ago, with global enterprises more dependent than ever on external suppliers for their consulting, marketing, IT, HR, legal and other service needs for agility and adaptability,” said Globality Chief Revenue Officer Keith Hausmann. “Without the right technology, processes and information in place, businesses historically will spend 10% to 30% more on outside services. Completing the source-to-pay process with this new integration ensures AGS customers have greater insights for all their high-value services, resulting in more efficient procurement decisions, faster speed to market and better supplier quality.”
Delivering a path to improved management of services spend, the partnership provides multiple advantages:
- Faster engagement: Increasing efficiencies and accelerating speed to market by automating procurement processes with AI-powered, self-serve sourcing
- Better supplier quality: Revealing the best-performing suppliers using data-enabled intelligence to facilitate continuous machine learning
- Increased user satisfaction: Boosting adoption of the overall procurement strategy and enhancing compliance through a consumer-like, intuitive sourcing experience
- Strategic transformation: Enabling better buying decisions with more compliant supplier engagement, competitively sourced spend and greater insights into what is delivered after the contract is signed
- End-to-end value realization: Identifying optimal solutions at the best available cost and incorporating feedback that makes future sourcing activity on the Platform even more robust and intelligent
With strategic sourcing increasingly viewed as a critical source of transformational innovation for global enterprises, companies are actively seeking ways to improve their bottom line and increase efficiency gains. Globality’s Platform transforms the sourcing of high-value services by automating the demand creation, supplier identification, proposal evaluation and statement of work (SOW) creation process with an intuitive self-serve experience. Companies can dynamically source the best-fit supplier for every complex service, while AGS manages delivery, generating actionable, real-time insights and identifying opportunities for additional savings.
“From opportunity to RFP, selection, management and performance tracking, an AGS and Globality solution closes the loop on strategy and execution to deliver a continuous cycle of performance improvement and an improved end-user experience,” said AGS Head of Procurement Solutions Strategy Jon Kesman. “This end-to-end solution ensures companies only contract for what they need and no longer leave significant dollars on the table with services being poorly sourced or left unmanaged after the contract is signed.”
“The AGS and Globality solution gives users faster engagement by modernizing and simplifying what can be a cumbersome RFP process when it comes to services and ensuring better supplier quality through continuous AI-driven learning, which increases end-user satisfaction and enhances compliance in the procurement process with its easy-to-use interface,” Kesman added.
To learn more about the partnership or schedule a demo, visit https://learn.allegisglobalsolutions.com/en-us/globality .
About Globality
Globality is a Silicon Valley-headquartered technology company co-founded by Joel Hyatt and Lior Delgo to revolutionize how companies buy and sell services. Through its AI-powered Platform and marketplace, Globality is bringing digital transformation to the sourcing industry. Globality’s AI digital solution replaces the archaic analog Request for Proposal, efficiently and effectively scoping needs, managing demand, matching companies with outstanding suppliers that meet their specific service needs and cutting the sourcing process from months to hours while delivering savings of 20% or more. In January 2021, Globality raised $138 million from Sienna Capital and the SoftBank Vision Fund, bringing the total investment it has raised since its founding five years ago to $310 million. For more information, visit Globality’s website at www.globality.com .
About Allegis Global Solutions
Allegis Global Solutions (AGS) is the leading provider of workforce solutions. AGS transforms the way the world acquires talent in order to deliver immediate and lasting impact. Through decades of industry experience, and with services across 60+ countries, AGS knows what it takes to innovate, consult, design and implement successful, creative and data-driven talent solutions across all workforce categories. Learn more at www.allegisglobalsolutions.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005144/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
